| 摘要 |
The description relates to methods of treating, preventing and/or managing macular degeneration by administering an immunomodulatory compound defined in the specification, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, or clathrate thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in the treatment of wet age-related macular degeneration are also disclosed.
|
